Referred to the House Committee on Energy and Commerce.
This bill amends the Federal Food, Drug, and Cosmetic Act to require nonvisual accessibility standards for certain medical devices with user interfaces that are intended for home use and are class II or III devices cleared, authorized, or approved after the statute's effective date. The standard requires that the user interface be as effective for blind or low-vision individuals as for sighted users in terms of access to information, interactions, privacy, independence, and ease of use.
Scope and timing: whether existing devices must be retrofitted or only new clearances are covered.
Relative to its intended legislative type, this bill is a clear substantive amendment to the FD&C Act that sets a performance standard and a timetable for implementing regulations to require nonvisual accessibility for certain home-use medical devices.
This bill amends the Federal Food, Drug, and Cosmetic Act to require nonvisual accessibility standards for certain medical devices with user interfaces that are intended for home use and are class II or III devices cleared, authorized, or approved after the statute's effective date.
The standard requires that the user interface be as effective for blind or low-vision individuals as for sighted users in terms of access to information, interactions, privacy, independence, and ease of use.
The Secretary (via FDA) must consult specified stakeholders, issue proposed regulations within one year and a final rule within two years of enactment, provide training for manufacturers, and may grant waivers where compliance would cause a fundamental alteration or undue hardship based on clear and convincing evidence.
On substance the bill is a targeted regulatory fix aimed at improving accessibility for blind and low-vision users of home medical devices — a goal that often draws sympathy across the aisle. The draft includes sensible implementation delays, consultation, and waiver authority, which reduce friction. However, it creates new FDA obligations and potential costs for device manufacturers and uses an enforcement mechanism (adulteration) that could attract industry resistance; without strong stakeholder coalition-building or inclusion in a broader legislative vehicle, progress beyond committee and floor consideration may be uneven.
Relative to its intended legislative type, this bill is a clear substantive amendment to the FD&C Act that sets a performance standard and a timetable for implementing regulations to require nonvisual accessibility for certain home-use medical devices. It integrates with existing statutory provisions and establishes waiver authority and stakeholder consultation.
Scope and timing: whether existing devices must be retrofitted or only new clearances are covered.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and timing: whether existing devices must be retrofitted or only new clearances are covered.
A liberal or left-leaning observer would likely view this bill positively as a civil-rights and disability-rights measure that promotes equity and independent access to healthcare technologies.
They would see it as closing an accessibility gap for blind and low-vision consumers who rely increasingly on home medical devices.
They would also welcome the consultation and training provisions, while urging stronger protections and expedited implementation where possible.
A centrist/moderate would generally favor the bill's goal of improving accessibility but would be attentive to implementation details, costs, and unintended consequences.
They would appreciate the statutory deadlines for rulemaking and the waiver mechanism, but would want clear guidance on what compliance requires and how FDA will avoid disrupting access to essential devices.
They would likely support the bill if it includes reasonable timelines, clear technical standards, and assistance for small firms to comply while preserving product availability and safety.
A mainstream conservative observer would be skeptical of a new federal mandate that imposes accessibility requirements on private medical-device manufacturers, citing regulatory burden and potential impacts on innovation, cost, and product availability.
They would be concerned that the adulteration penalty and the prospect of devices being barred could disrupt supply and raise costs.
However, they might view the statutory waiver and stakeholder consultation as useful; they would prefer approaches that rely more on incentives, voluntary standards, or state-level solutions rather than broad federal mandates.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance the bill is a targeted regulatory fix aimed at improving accessibility for blind and low-vision users of home medical devices — a goal that often draws sympathy across the aisle. The draft includes sensible implementation delays, consultation, and waiver authority, which reduce friction. However, it creates new FDA obligations and potential costs for device manufacturers and uses an enforcement mechanism (adulteration) that could attract industry resistance; without strong stakeholder coalition-building or inclusion in a broader legislative vehicle, progress beyond committee and floor consideration may be uneven.
The bill has not accumulated any surfaced votes yet.
Scope and timing: whether existing devices must be retrofitted or only new clearances are covered.
On substance the bill is a targeted regulatory fix aimed at improving accessibility for blind and low-vision users of home medical devices…
Relative to its intended legislative type, this bill is a clear substantive amendment to the FD&C Act that sets a performance standard and a timetable for implementing regulations to require nonvisual accessibility for…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.